Table 5.

Linear regression analysis of the effect of treatment group on secondary outcomes

Outcome: 8-week change*		Chlorhexidine (N=20)		Placebo (N=20)	Treatment group†	P value‡
	N	Mean±SD	N	Mean±SD	Estimate (95% CI)
BCSS	19	−0.3±1.9	18	−0.1±1.5	−0.28 (−1.45 to 0.89)	0.630
SGRQ total score	20	−4.7±8.0	20	1.7±8.9	−6.22 (−11.87 to 0.57)	0.032
Activity domain	20	−0.5±9.1	20	3.9±12.9	−3.84 (−10.92 to 3.24)	0.279
Impacts domain	20	−5.4±12.6	20	0.7±10.0	−5.46 (−12.92 to 1.99)	0.146
Symptoms domain	20	−10.1±15.2	20	0.8±18.8	−6.81 (−17.82 to 4.19)	0.217

*Each model is adjusted for the baseline value of each outcome.

†Treatment group is coded as chlorhexidine=1, placebo=0.

‡The p-value is for the comparison of chlorhexidine versus placebo.

BCSS, Breathlessness, Cough and Sputum Scale; SGRQ, St. George’s Respiratory Questionnaire.